HER2-low expression is highly unstable during breast cancer evolution suggesting that biopsies of locoregional relapses or distant metastases might reveal potentially new therapeutic opportunities for some patients, research suggests. Presenting at ESMO Breast Cancer 2021, Dr Federica Miglietta said access to anti-HER2 agents is currently restricted to patients with HER2-positive patients as defined by IHC ...
ESMO 2021: Instability in HER2 expression over disease progression opens up treatment options
By Mardi Chapman
11 May 2021